Select Vaccines signs agreement to develop Hep C test
Thursday, 25 March, 2004
Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
"It's one in a series of MTAs which will put us in the best possible position to have a rapid test that works with a number of rapid systems in the marketplace," said CEO Dr Martin Soust.
Soust said the agreement would cut at least three months off the timeframe required to develop the point-of-care test, and would allow the company to compare multiple rapid systems concurrently.
The MTA also contains the provision that the supplier company will be able to exercise rights to license or on-license any IP that arises from successful development.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
